GOTHENBURG, Sweden, Aug. 14, 2025 /PRNewswire/ -- CEO Dr Martin Edlund: "As the leading pioneer in Ocean Renewable Energy, Minesto moves on with more determination and...
Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets
Increased Total...
Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets
Increased Total...
Subsequent to the end of the quarter, completed the previously announced transaction to internalize its investment management functionPortfolio assets generate Total Income of $44.1...
Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update.
First Half Revenue of $45,118Prepaid subscription fees received from customers for our SaaS service were $1.5 Million.
HONG KONG, Aug. 13, 2025 /PRNewswire/ -- FiEE,...
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BellRing Brands, Inc. (“BellRing” or the “Company”) (NYSE: BRBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
WUHAN, China, Aug. 13, 2025 /PRNewswire/ -- China Automotive Systems, Inc. (NASDAQ: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier in...
Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.
CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto" or the "Company") is pleased to report operating and financial results for the second quarter of 2025.
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...
TORRANCE, Calif., Aug. 12, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ: PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle...